

Invited Paper, For, Proceedings, 13th Radiochemical Conference, Marianske Lazne, Czech Republic, April 19-24, 1998, in press.

CONF-980446--

PRODUCTION OF MEDICAL RADIOISOTOPES IN THE ORNL HIGH FLUX ISOTOPE REACTOR (HFIR) FOR CANCER TREATMENT AND ARTERIAL RESTENOSIS THERAPY AFTER PTCA

RECEIVED

JUN 25 1998

OSTI

¹F. F. (Russ) KNAPP, Jr., ¹A. L. BEETS, ¹S. MIRZADEH, ²C. W. ALEXANDER
and ³R. L. HOBBS

¹ *Nuclear Medicine Group, Life Sciences Division*
² *Chemical Technology Division*
² *Research Reactors Division*
Oak Ridge National Laboratory (ORNL)
Oak Ridge, TN 37831-6229, U.S.A.

RECEIVED

MAY 14 1998

OSTI

For reprints and correspondence contact: F. F. (Russ) Knapp, Jr., Group Leader, Nuclear Medicine, Oak Ridge National Laboratory (ORNL), Building 4501, Mail Stop 6229, P.O. Box 2008, Oak Ridge, TN 37831-6229; Tel. (423) 574-6225; FAX (423) 574-6226; E-mail <jkp@ornl.gov>.

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED *ph*

MASTER

Research at ORNL is supported by the U.S. Department of Energy (DOE), under contract DE-AC05-96OR22464 with Lockheed Martin Energy Research Corporation.

The submitted manuscript has been authored by a contractor of the U.S. Government under contract No. DE-AC05-96OR22464. Accordingly, the U.S. Government retains a nonexclusive, royalty-free license to publish or reproduce the published form of this contribution, or allow others to do so, for U.S. Government purposes.